-
1
-
-
0034771945
-
Interaction of human immunodeficiency virus type 1 Vif with Gag and Gag-Pol precursors: Co-encapsidation and interference with viral protease-mediated Gag processing
-
Bardy M, Gay B, Pebernard S, Chazal N, Courcoul M, Vigne R, Decroly E, Boulanger P. 2001. Interaction of human immunodeficiency virus type 1 Vif with Gag and Gag-Pol precursors: Co-encapsidation and interference with viral protease-mediated Gag processing. J Gen Virol 82:2719-2733.
-
(2001)
J Gen Virol
, vol.82
, pp. 2719-2733
-
-
Bardy, M.1
Gay, B.2
Pebernard, S.3
Chazal, N.4
Courcoul, M.5
Vigne, R.6
Decroly, E.7
Boulanger, P.8
-
2
-
-
0031724008
-
Resistance to human immunodeficiency virus type 1 protease inhibitors
-
Boden D, Markowitz M. 1998. Resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother 42:2775-2783.
-
(1998)
Antimicrob Agents Chemother
, vol.42
, pp. 2775-2783
-
-
Boden, D.1
Markowitz, M.2
-
3
-
-
0028915063
-
Human immunodeficiency virus type 1 Vif-mutant particles from restrictive cells: Role of Vif in correct particle assembly and infectivity
-
Borman AM, Quillent C, Charneau P, Dauguet C, Clavel F. 1995. Human immunodeficiency virus type 1 Vif-mutant particles from restrictive cells: Role of Vif in correct particle assembly and infectivity. J Virol 69:2058-2067.
-
(1995)
J Virol
, vol.69
, pp. 2058-2067
-
-
Borman, A.M.1
Quillent, C.2
Charneau, P.3
Dauguet, C.4
Clavel, F.5
-
4
-
-
0030812551
-
Human immunodeficiency virus type 1 Vif protein binds to the Pr55Gag precursor
-
Bouyac M, Courcoul M, Bertoia G, Baudat Y, Gabuzda D, Blanc D, Chazal N, Boulanger P, Sire J, Vigne R, Spire B. 1997. Human immunodeficiency virus type 1 Vif protein binds to the Pr55Gag precursor. J Virol 71:9358-9365.
-
(1997)
J Virol
, vol.71
, pp. 9358-9365
-
-
Bouyac, M.1
Courcoul, M.2
Bertoia, G.3
Baudat, Y.4
Gabuzda, D.5
Blanc, D.6
Chazal, N.7
Boulanger, P.8
Sire, J.9
Vigne, R.10
Spire, B.11
-
6
-
-
0031015475
-
Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors
-
Croteau G, Doyon L, Thibeault D, McKercher G, Pilote L, Lamarre D. 1997. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors. J Virol 71:1089-1096.
-
(1997)
J Virol
, vol.71
, pp. 1089-1096
-
-
Croteau, G.1
Doyon, L.2
Thibeault, D.3
McKercher, G.4
Pilote, L.5
Lamarre, D.6
-
7
-
-
0024784403
-
Cleavage of HIV-1 gag polyprotein synthesized in vitro: Sequential cleavage by the viral protease
-
Erickson-Viitanen S, Manfredi J, Viitanen P, Tribe DE, Tritch R, Hutchison CA III, Loeb DD, Swanstrom R. 1989. Cleavage of HIV-1 gag polyprotein synthesized in vitro: Sequential cleavage by the viral protease. AIDS Res Hum Retroviruses 5:577-591.
-
(1989)
AIDS Res Hum Retroviruses
, vol.5
, pp. 577-591
-
-
Erickson-Viitanen, S.1
Manfredi, J.2
Viitanen, P.3
Tribe, D.E.4
Tritch, R.5
Hutchison III, C.A.6
Loeb, D.D.7
Swanstrom, R.8
-
8
-
-
0026649561
-
Role of vif in replication of human immunodeficiency virus type l in CD4+ T lymphocytes
-
Gabuzda DH, Lawrence K, Langhoff E, Terwilliger E, Dorfman T, Haseltine WA, Sodroski J. 1992. Role of vif in replication of human immunodeficiency virus type l in CD4+ T lymphocytes. J Virol 66:6489-6495.
-
(1992)
J Virol
, vol.66
, pp. 6489-6495
-
-
Gabuzda, D.H.1
Lawrence, K.2
Langhoff, E.3
Terwilliger, E.4
Dorfman, T.5
Haseltine, W.A.6
Sodroski, J.7
-
9
-
-
0026070511
-
A specific inhibitor of cysteine proteases impairs a Vif-dependent modification of human immunodeficiency virus type 1 Env protein
-
Guy B, Geist M, Dott K, Spehner D, Kieny MP, Lecocq JP. 1991. A specific inhibitor of cysteine proteases impairs a Vif-dependent modification of human immunodeficiency virus type 1 Env protein. J Virol 65:1325-1331.
-
(1991)
J Virol
, vol.65
, pp. 1325-1331
-
-
Guy, B.1
Geist, M.2
Dott, K.3
Spehner, D.4
Kieny, M.P.5
Lecocq, J.P.6
-
10
-
-
0001917813
-
Mutations in retrovirus genes associated with drug resistance
-
Kuiken C, editor
-
Hammond J, Calef C, Larder B, Schinazi R, Mellors JW. 1999. Mutations in retrovirus genes associated with drug resistance. In: Kuiken C, editor. Human retroviruses and AIDS. pp 542-591.
-
(1999)
Human Retroviruses and AIDS
, pp. 542-591
-
-
Hammond, J.1
Calef, C.2
Larder, B.3
Schinazi, R.4
Mellors, J.W.5
-
11
-
-
0034633803
-
Characterization of human immunodeficiency virus type 1 vif gene in long-term asymptomatic individuals
-
Hassaine G, Agostini I, Candotti D, Bessou G, Caballero M, Agut H, Autran B, Barthalay Y, Vigne R. 2000. Characterization of human immunodeficiency virus type 1 vif gene in long-term asymptomatic individuals. Virology 276:169-180.
-
(2000)
Virology
, vol.276
, pp. 169-180
-
-
Hassaine, G.1
Agostini, I.2
Candotti, D.3
Bessou, G.4
Caballero, M.5
Agut, H.6
Autran, B.7
Barthalay, Y.8
Vigne, R.9
-
13
-
-
0030740060
-
Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro
-
Kotler M, Simm M, Zhao YS, Sova P, Chao W, Ohnona SF, Roller R, Krachmarov C, Potash MJ, Volsky DJ. 1997. Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro. J Virol 71:5774-5781.
-
(1997)
J Virol
, vol.71
, pp. 5774-5781
-
-
Kotler, M.1
Simm, M.2
Zhao, Y.S.3
Sova, P.4
Chao, W.5
Ohnona, S.F.6
Roller, R.7
Krachmarov, C.8
Potash, M.J.9
Volsky, D.J.10
-
15
-
-
0038363470
-
Hypermutation of HIV-1 DNA in the absence of the Vif protein
-
Lecossier D, Bouchonnet F, Clavel F, Hance AJ. 2003. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 300:1112.
-
(2003)
Science
, vol.300
, pp. 1112
-
-
Lecossier, D.1
Bouchonnet, F.2
Clavel, F.3
Hance, A.J.4
-
16
-
-
0027980114
-
Cysteine residues in the Vif protein of human immunodeficiency virus type 1 are essential for viral infectivity
-
Ma XY, Sova P, Chao W, Volsky DJ. 1994. Cysteine residues in the Vif protein of human immunodeficiency virus type 1 are essential for viral infectivity. J Virol 68:1714-1720.
-
(1994)
J Virol
, vol.68
, pp. 1714-1720
-
-
Ma, X.Y.1
Sova, P.2
Chao, W.3
Volsky, D.J.4
-
17
-
-
0031797865
-
An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein
-
Madani N, Kabat D. 1998. An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein. J Virol 72:10251-10255.
-
(1998)
J Virol
, vol.72
, pp. 10251-10255
-
-
Madani, N.1
Kabat, D.2
-
18
-
-
0038681023
-
Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts
-
Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. 2003. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424:99-103.
-
(2003)
Nature
, vol.424
, pp. 99-103
-
-
Mangeat, B.1
Turelli, P.2
Caron, G.3
Friedli, M.4
Perrin, L.5
Trono, D.6
-
19
-
-
0344845196
-
HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation
-
Marin M, Rose KM, Kozak SL, Kabat D. 2003. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nat Med 9:1398-1403.
-
(2003)
Nat Med
, vol.9
, pp. 1398-1403
-
-
Marin, M.1
Rose, K.M.2
Kozak, S.L.3
Kabat, D.4
-
21
-
-
0027447213
-
Cell-dependent requirement of human immunodeficiency virus type 1 Vif protein for maturation of virus particles
-
Sakai H, Shibata R, Sakuragi J, Sakuragi S, Kawamura M, Adachi A. 1993. Cell-dependent requirement of human immunodeficiency virus type 1 Vif protein for maturation of virus particles. J Virol 67:1663-1666.
-
(1993)
J Virol
, vol.67
, pp. 1663-1666
-
-
Sakai, H.1
Shibata, R.2
Sakuragi, J.3
Sakuragi, S.4
Kawamura, M.5
Adachi, A.6
-
22
-
-
0037043699
-
Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein
-
Sheehy AM, Gaddis NC, Choi JD, Malim MH. 2002. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418:646-650.
-
(2002)
Nature
, vol.418
, pp. 646-650
-
-
Sheehy, A.M.1
Gaddis, N.C.2
Choi, J.D.3
Malim, M.H.4
-
23
-
-
0344413641
-
The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif
-
Sheehy AM, Gaddis NC, Malim MH. 2003. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat Med 9:1404-1407.
-
(2003)
Nat Med
, vol.9
, pp. 1404-1407
-
-
Sheehy, A.M.1
Gaddis, N.C.2
Malim, M.H.3
-
24
-
-
0029056704
-
Aberrant Gag protein composition of a human immunodeficiency virus type 1 vif mutant produced in primary lymphocytes
-
Simm M, Shahabuddin M, Chao W, Allan JS, Volsky DJ. 1995. Aberrant Gag protein composition of a human immunodeficiency virus type 1 vif mutant produced in primary lymphocytes. J Virol 69 :4582-4586.
-
(1995)
J Virol
, vol.69
, pp. 4582-4586
-
-
Simm, M.1
Shahabuddin, M.2
Chao, W.3
Allan, J.S.4
Volsky, D.J.5
-
25
-
-
0029956256
-
The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes
-
Simon JH, Malim MH. 1996. The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes. J Virol 70:5297-5305.
-
(1996)
J Virol
, vol.70
, pp. 5297-5305
-
-
Simon, J.H.1
Malim, M.H.2
-
26
-
-
0031788565
-
Evidence for a newly discovered cellular anti-HIV-1 phenotype
-
Simon JH, Gaddis NC, Fouchier RA, Malim MH. 1998. Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nat Med 4:1397-1400.
-
(1998)
Nat Med
, vol.4
, pp. 1397-1400
-
-
Simon, J.H.1
Gaddis, N.C.2
Fouchier, R.A.3
Malim, M.H.4
-
27
-
-
0033053198
-
Mutational analysis of the human immunodeficiency virus type 1 Vif protein
-
Simon JH, Sheehy AM, Carpenter EA, Fouchier RA, Malim MH. 1999. Mutational analysis of the human immunodeficiency virus type 1 Vif protein. J Virol 73:2675-2681.
-
(1999)
J Virol
, vol.73
, pp. 2675-2681
-
-
Simon, J.H.1
Sheehy, A.M.2
Carpenter, E.A.3
Fouchier, R.A.4
Malim, M.H.5
-
28
-
-
0141638436
-
HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability
-
Stopak K, de Noronha C, Yonemoto W, Greene WC. 2003. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol Cell 12:591-601.
-
(2003)
Mol Cell
, vol.12
, pp. 591-601
-
-
Stopak, K.1
De Noronha, C.2
Yonemoto, W.3
Greene, W.C.4
-
29
-
-
0023267788
-
The HIV 'A' (sor) gene product is essential for virus infectivity
-
Strebel K, Daugherty D, Clouse K, Cohen D, Folks T, Martin MA. 1987. The HIV 'A' (sor) gene product is essential for virus infectivity. Nature 328:728-730.
-
(1987)
Nature
, vol.328
, pp. 728-730
-
-
Strebel, K.1
Daugherty, D.2
Clouse, K.3
Cohen, D.4
Folks, T.5
Martin, M.A.6
-
30
-
-
0038182982
-
Identification of a transmission chain of HIV Type 1 containing drug resistance associated mutations
-
Taylor S, Cane P, Hue S, Xu L, Wrin T, Lie Y, Hellman N, Petropoulos C, Workman J, Ratcliffe D, Choudhury B, Pillay D. 2003. Identification of a transmission chain of HIV Type 1 containing drug resistance associated mutations. AIDS Res Hum Retroviruses 19:353-361.
-
(2003)
AIDS Res Hum Retroviruses
, vol.19
, pp. 353-361
-
-
Taylor, S.1
Cane, P.2
Hue, S.3
Xu, L.4
Wrin, T.5
Lie, Y.6
Hellman, N.7
Petropoulos, C.8
Workman, J.9
Ratcliffe, D.10
Choudhury, B.11
Pillay, D.12
-
31
-
-
0030769354
-
Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites
-
Zhang YM, Imamichi H, Imamichi T, Lane HC, Falloon J, Vasudevachari MB, Salzman NP. 1997. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol 71:6662-6670.
-
(1997)
J Virol
, vol.71
, pp. 6662-6670
-
-
Zhang, Y.M.1
Imamichi, H.2
Imamichi, T.3
Lane, H.C.4
Falloon, J.5
Vasudevachari, M.B.6
Salzman, N.P.7
-
32
-
-
0038004471
-
The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA
-
Zhang H, Yang B, Pomerantz RJ, Zhang CM, Arunachalam SC, Gao L. 2003. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 424:94-98.
-
(2003)
Nature
, vol.424
, pp. 94-98
-
-
Zhang, H.1
Yang, B.2
Pomerantz, R.J.3
Zhang, C.M.4
Arunachalam, S.C.5
Gao, L.6
|